,question,gt_rec1,gt_rec2,gt_rec3,gt_avoid,gt_reason,prompt,raw_answer,answer1,pro1,cons1,answer2,pro2,cons2,source1,source2,source3,source4,source5,source6
0,"40 year old male with newly diagnosed moderate UC and articular extraintestinal manifestations
",Infliximab,Tofacitinib,,vedolizumab,IFX is ideal choice as biologically naïve with EIM.,"Make reference to the context given to assess the scenario. If you do not know the answer. just say that ""I don't know"", don't try to make up an answer.
You are a physician assistant giving advice on treatment for moderate to severe ulcerative colitis (UC). Perform the following step

ANALYSE the given patient profile based on given query based on the following criteria:
- Freshly treated patient or patient under maintenance
- Prior response to Infliximab
- Prior failure to Anti-TNF agents
- Prior failure to Vedolizumab
- Age
- Pregnancy
- Extraintestinale manifestations
- Pouchitis

FINALLY RETURN up to 2 TOP choices of biological drugs given patient profile. Explain the PROS and CONS of the 2 choices.

summaries

The output should be formatted as a JSON instance that conforms to the JSON schema below.

As an example, for the schema {""properties"": {""foo"": {""title"": ""Foo"", ""description"": ""a list of strings"", ""type"": ""array"", ""items"": {""type"": ""string""}}}, ""required"": [""foo""]}}
the object {""foo"": [""bar"", ""baz""]} is a well-formatted instance of the schema. The object {""properties"": {""foo"": [""bar"", ""baz""]}} is not well-formatted.

Here is the output schema:
```
{""properties"": {""drug_name"": {""title"": ""Drug Name"", ""description"": ""Name of the drug"", ""type"": ""string""}, ""advantages"": {""title"": ""Advantages"", ""description"": ""Advantages of the drug "", ""type"": ""string""}, ""disadvantages"": {""title"": ""Disadvantages"", ""description"": ""Disadvantages of the drug"", ""type"": ""string""}}, ""required"": [""drug_name"", ""advantages"", ""disadvantages""]}
```

Question: question
Answer:
",I don't know.,,,,,,,"title:

filename: otad009.pdf

page: 14

text: moderately to severely active UC.
Supplementary Data
Supplementary data is available at Crohn’s and Colitis 360
online.
Funding
This work was supported by AbbVie Inc., who funded this
study and participated in the study design, research, analy-
sis, data collection, interpretation of data, reviewing, and ap-
proval of the publication. All authors had access to relevant
data and participated in the drafting, review, and approval of
this publication. No honoraria or payments were made for
authorship. Medicus Economics LLC has received funding
from AbbVie Inc. for technical writing assistance.
Authors’ Contributions
Remo Panaccione: Writing—review and editing (equal), Eric
B. Collins: Methodology (supporting), formal analysis (e-","title: First- and Second-Line Pharmacotherapies for Patients With Moderate to Severely Active Ulcerative Colitis: An Updated Network Meta-Analysis

filename: PIIS1542356520300446.pdf

page: 6

text: clinical
remission
and
endoscopic
improvement
in biologic-naïve patients
with moderate to severely
active ulcerative colitis. (B)
Relative
efﬁcacy
of
different interventions for
induction of clinical remis-
sion
and
endoscopic
improvement
in
patients
with moderate to severely
active
ulcerative
colitis
with prior exposure to tu-
mor necrosis factor (TNF)⍺
antagonists. SUCRA, sur-
face under the cumulative
ranking.
September 2020
Management of Moderate–Severe UC 2185","title: First- and Second-Line Pharmacotherapies for Patients With Moderate to Severely Active Ulcerative Colitis: An Updated Network Meta-Analysis

filename: PIIS1542356520300446.pdf

page: 5

text: Table 1. Overall, the median average age of patients was
41 years (interquartile range, 40–42 y), and 60%
(interquartile range, 56%–63%) were men. The median
disease duration was 6.7 years (interquartile range,
6.0–7.8 y), and 49% (interquartile range, 46%–55%) of
patients had extensive colitis. A median of 40% (inter-
quartile range, 30%–50%) of patients were treated with
concomitant immunomodulators, and 51% (interquartile
range, 45%–57%) were on corticosteroids at baseline.
Patients across all trials and treatment arms were com-
parable in terms of baseline prognostic variables, inclu-
sion/exclusion
criteria,
and
co-interventions.
All
outcomes were assessed uniformly based on the stan-","title: Approach to the Management of Recently Diagnosed Inflammatory Bowel Disease Patients: A User's Guide for Adult and Pediatric Gastroenterologists

filename: agrawal.pdf

page: 2

text: with an increased risk (odds ratio [OR], 2.1; 95% CI, 1.3–
3.6) of disabling disease 5 years after diagnosis, including
higher rates of surgery, hospitalization, steroid dependence,
and disease recurrence.42,43 In UC, younger age at diagnosis
is linked to more frequent relapses, colectomy, and colo-
rectal cancer.44,45 There are conﬂicting data on the disease
course in the very-early-onset IBD population of patients
diagnosed before age 6 years, with studies reporting both
similar
and
worse
outcomes
in
very-early-onset
IBD
compared to the general pediatric population.46 Similar to
the youngest patients with IBD, elderly-onset IBD (diag-
nosed at 60–65 years of age) has conﬂicting evidence on",,
1,"70 year old female with newly diagnosed severe UC
",Ustekinumab,Vedolizumab,,Infliximab,"Given advanced age, IFX not preferred as first choice","Make reference to the context given to assess the scenario. If you do not know the answer. just say that ""I don't know"", don't try to make up an answer.
You are a physician assistant giving advice on treatment for moderate to severe ulcerative colitis (UC). Perform the following step

ANALYSE the given patient profile based on given query based on the following criteria:
- Freshly treated patient or patient under maintenance
- Prior response to Infliximab
- Prior failure to Anti-TNF agents
- Prior failure to Vedolizumab
- Age
- Pregnancy
- Extraintestinale manifestations
- Pouchitis

FINALLY RETURN up to 2 TOP choices of biological drugs given patient profile. Explain the PROS and CONS of the 2 choices.

summaries

The output should be formatted as a JSON instance that conforms to the JSON schema below.

As an example, for the schema {""properties"": {""foo"": {""title"": ""Foo"", ""description"": ""a list of strings"", ""type"": ""array"", ""items"": {""type"": ""string""}}}, ""required"": [""foo""]}}
the object {""foo"": [""bar"", ""baz""]} is a well-formatted instance of the schema. The object {""properties"": {""foo"": [""bar"", ""baz""]}} is not well-formatted.

Here is the output schema:
```
{""properties"": {""drug_name"": {""title"": ""Drug Name"", ""description"": ""Name of the drug"", ""type"": ""string""}, ""advantages"": {""title"": ""Advantages"", ""description"": ""Advantages of the drug "", ""type"": ""string""}, ""disadvantages"": {""title"": ""Disadvantages"", ""description"": ""Disadvantages of the drug"", ""type"": ""string""}}, ""required"": [""drug_name"", ""advantages"", ""disadvantages""]}
```

Question: question
Answer:
",I don't know.,,,,,,,"title: Approach to the Management of Recently Diagnosed Inflammatory Bowel Disease Patients: A User's Guide for Adult and Pediatric Gastroenterologists

filename: agrawal.pdf

page: 2

text: with an increased risk (odds ratio [OR], 2.1; 95% CI, 1.3–
3.6) of disabling disease 5 years after diagnosis, including
higher rates of surgery, hospitalization, steroid dependence,
and disease recurrence.42,43 In UC, younger age at diagnosis
is linked to more frequent relapses, colectomy, and colo-
rectal cancer.44,45 There are conﬂicting data on the disease
course in the very-early-onset IBD population of patients
diagnosed before age 6 years, with studies reporting both
similar
and
worse
outcomes
in
very-early-onset
IBD
compared to the general pediatric population.46 Similar to
the youngest patients with IBD, elderly-onset IBD (diag-
nosed at 60–65 years of age) has conﬂicting evidence on","title: First- and Second-Line Pharmacotherapies for Patients With Moderate to Severely Active Ulcerative Colitis: An Updated Network Meta-Analysis

filename: PIIS1542356520300446.pdf

page: 6

text: clinical
remission
and
endoscopic
improvement
in biologic-naïve patients
with moderate to severely
active ulcerative colitis. (B)
Relative
efﬁcacy
of
different interventions for
induction of clinical remis-
sion
and
endoscopic
improvement
in
patients
with moderate to severely
active
ulcerative
colitis
with prior exposure to tu-
mor necrosis factor (TNF)⍺
antagonists. SUCRA, sur-
face under the cumulative
ranking.
September 2020
Management of Moderate–Severe UC 2185","title:

filename: otad009.pdf

page: 1

text: 2
Efficacy and Safety of Advanced Therapies
incidence ranges from 9 to 20 cases per 100 000 per year with
higher incidence in North America and Northern Europe.1
The advanced therapeutic armamentarium for adults
with moderately to severely active UC is rapidly evolving.
For over 20 years, biologics targeting specific inflamma-
tory pathways have been the mainstay, beginning with those
targeting tumor necrosis alpha (TNFi; eg, infliximab [INF],
adalimumab [ADA], and golimumab [GOL]) followed by
biologics with other modes of action (eg, vedolizumab [VED]
and ustekinumab [UST]). However, treatment limitations for
moderately to severely active UC remain, including primary
nonresponse, secondary loss of response, immunogenicity, and","title:

filename: otad009.pdf

page: 0

text: Introduction
Ulcerative colitis (UC) is a chronic inflammatory bowel dis-
ease that affects the colorectum and is clinically characterized
by bloody diarrhea, urgency, tenesmus, abdominal pain, ma-
laise, weight loss, and fever. Disease onset commonly occurs
between the ages of 15 and 30 years and the annual global
© The Author(s) 2023. Published by Oxford University Press on behalf of Crohn's & Colitis Foundation.
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/),
which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.",,
2,"35 year old male with known moderate UC with prior exposure to infliximab but has worsening colitis on endoscopy despite compliance
",Tofacitinib,Ustekinumab,,,Testing 2nd line treatment to patients previously exposed to anti-TNFa,"Make reference to the context given to assess the scenario. If you do not know the answer. just say that ""I don't know"", don't try to make up an answer.
You are a physician assistant giving advice on treatment for moderate to severe ulcerative colitis (UC). Perform the following step

ANALYSE the given patient profile based on given query based on the following criteria:
- Freshly treated patient or patient under maintenance
- Prior response to Infliximab
- Prior failure to Anti-TNF agents
- Prior failure to Vedolizumab
- Age
- Pregnancy
- Extraintestinale manifestations
- Pouchitis

FINALLY RETURN up to 2 TOP choices of biological drugs given patient profile. Explain the PROS and CONS of the 2 choices.

summaries

The output should be formatted as a JSON instance that conforms to the JSON schema below.

As an example, for the schema {""properties"": {""foo"": {""title"": ""Foo"", ""description"": ""a list of strings"", ""type"": ""array"", ""items"": {""type"": ""string""}}}, ""required"": [""foo""]}}
the object {""foo"": [""bar"", ""baz""]} is a well-formatted instance of the schema. The object {""properties"": {""foo"": [""bar"", ""baz""]}} is not well-formatted.

Here is the output schema:
```
{""properties"": {""drug_name"": {""title"": ""Drug Name"", ""description"": ""Name of the drug"", ""type"": ""string""}, ""advantages"": {""title"": ""Advantages"", ""description"": ""Advantages of the drug "", ""type"": ""string""}, ""disadvantages"": {""title"": ""Disadvantages"", ""description"": ""Disadvantages of the drug"", ""type"": ""string""}}, ""required"": [""drug_name"", ""advantages"", ""disadvantages""]}
```

Question: question
Answer:
","[
  {
    ""drug_name"": ""Vedolizumab"",
    ""advantages"": ""Vedolizumab is ranked highly for inducing endoscopic improvement in biologic-naïve patients with moderate–severe ulcerative colitis. It can be a good option for patients who have had prior exposure to TNF antagonists like infliximab."",
    ""disadvantages"": ""The patient may not respond to Vedolizumab as well if they have had prior exposure to TNF antagonists. The effectiveness of the drug may also vary from patient to patient.""
  },
  {
    ""drug_name"": ""Ustekinumab"",
    ""advantages"": ""Ustekinumab can be used if the patient has prior exposure to TNF antagonists. It is also effective in inducing endoscopic improvement in patients with moderate to severe ulcerative colitis."",
    ""disadvantages"": ""The effectiveness of Ustekinumab can vary from patient to patient. It may not be as effective as other drugs like infliximab or vedolizumab in inducing endoscopic improvement.""
  }
]",Vedolizumab,Vedolizumab is ranked highly for inducing endoscopic improvement in biologic-naïve patients with moderate–severe ulcerative colitis. It can be a good option for patients who have had prior exposure to TNF antagonists like infliximab.,The patient may not respond to Vedolizumab as well if they have had prior exposure to TNF antagonists. The effectiveness of the drug may also vary from patient to patient.,Ustekinumab,Ustekinumab can be used if the patient has prior exposure to TNF antagonists. It is also effective in inducing endoscopic improvement in patients with moderate to severe ulcerative colitis.,The effectiveness of Ustekinumab can vary from patient to patient. It may not be as effective as other drugs like infliximab or vedolizumab in inducing endoscopic improvement.,"title: First- and Second-Line Pharmacotherapies for Patients With Moderate to Severely Active Ulcerative Colitis: An Updated Network Meta-Analysis

filename: PIIS1542356520300446.pdf

page: 6

text: clinical
remission
and
endoscopic
improvement
in biologic-naïve patients
with moderate to severely
active ulcerative colitis. (B)
Relative
efﬁcacy
of
different interventions for
induction of clinical remis-
sion
and
endoscopic
improvement
in
patients
with moderate to severely
active
ulcerative
colitis
with prior exposure to tu-
mor necrosis factor (TNF)⍺
antagonists. SUCRA, sur-
face under the cumulative
ranking.
September 2020
Management of Moderate–Severe UC 2185","title: First- and Second-Line Pharmacotherapies for Patients With Moderate to Severely Active Ulcerative Colitis: An Updated Network Meta-Analysis

filename: PIIS1542356520300446.pdf

page: 1

text: needed to inform clinical decision-making with
greater conﬁdence.
Implications for patient care
Patients with moderate to severely active ulcerative
colitis should receive inﬂiximab or vedolizumab as
ﬁrst-line therapy, or ustekinumab or tofacitinib if
they have prior exposure to TNF antagonists.
2180 Singh et al
Clinical Gastroenterology and Hepatology Vol. 18, No. 10","title: First- and Second-Line Pharmacotherapies for Patients With Moderate to Severely Active Ulcerative Colitis: An Updated Network Meta-Analysis

filename: PIIS1542356520300446.pdf

page: 1

text: colitis.
Studies
included
in
these
meta-
analyses were phase II or III randomized controlled
trials (RCTs) that met the following inclusion criteria:
(1) patients: adults (age, >18 y) with moderate to
severe ulcerative colitis (Mayo Clinic score of 6–12,
with an endoscopic subscore of 2 or 3) who were
either
treatment-naïve
(ﬁrst-line)
or
previously
exposed to TNFa antagonists (second-line); (2) inter-
vention: biologic therapy with inﬂiximab, adalimumab,
golimumab, vedolizumab, tofacitinib, or ustekinumab,
with a minimum duration of therapy of 14 days; (3)
comparator: another active intervention or placebo;
and (4) outcome: induction of clinical remission (Mayo
Clinic score of �2 with no individual subscore of >1)","title: First- and Second-Line Pharmacotherapies for Patients With Moderate to Severely Active Ulcerative Colitis: An Updated Network Meta-Analysis

filename: PIIS1542356520300446.pdf

page: 7

text: mates (OR, 1.32; 95% CI, 0.73–2.37) (Table 2). Overall,
inﬂiximab (SUCRA, 0.95) and vedolizumab (SUCRA, 0.76)
were ranked highest for inducing endoscopic improve-
ment in biologic-naïve patients with moderate–severe
ulcerative colitis (Figure 2A). With an estimated pla-
cebo rate of achieving endoscopic improvement of 30%
in induction trials, we estimated that 58.7%, 40.4%,
42.7%, 51.9%, 46.5%, and 44.4% of inﬂiximab-, adali-
mumab-, golimumab-, vedolizumab-, tofacitinib-, and
ustekinumab-treated patients, respectively, would ach-
ieve induction of endoscopic improvement.
Second-line
pharmacotherapy
for
moderate–severe
ulcerative colitis. Overall, 7 RCTs including 1580 pa-
tients with moderate–severe ulcerative colitis with prior",,
3,"60 year old female with newly diagnosed moderate UC with a background of congestive cardiac failure
",Ustekinumab,Vedolizumab,,Tofacitinib,Testing contraindications to first line IFX. TFC not recommended because of increased LDL-C and MACE risk,"Make reference to the context given to assess the scenario. If you do not know the answer. just say that ""I don't know"", don't try to make up an answer.
You are a physician assistant giving advice on treatment for moderate to severe ulcerative colitis (UC). Perform the following step

ANALYSE the given patient profile based on given query based on the following criteria:
- Freshly treated patient or patient under maintenance
- Prior response to Infliximab
- Prior failure to Anti-TNF agents
- Prior failure to Vedolizumab
- Age
- Pregnancy
- Extraintestinale manifestations
- Pouchitis

FINALLY RETURN up to 2 TOP choices of biological drugs given patient profile. Explain the PROS and CONS of the 2 choices.

summaries

The output should be formatted as a JSON instance that conforms to the JSON schema below.

As an example, for the schema {""properties"": {""foo"": {""title"": ""Foo"", ""description"": ""a list of strings"", ""type"": ""array"", ""items"": {""type"": ""string""}}}, ""required"": [""foo""]}}
the object {""foo"": [""bar"", ""baz""]} is a well-formatted instance of the schema. The object {""properties"": {""foo"": [""bar"", ""baz""]}} is not well-formatted.

Here is the output schema:
```
{""properties"": {""drug_name"": {""title"": ""Drug Name"", ""description"": ""Name of the drug"", ""type"": ""string""}, ""advantages"": {""title"": ""Advantages"", ""description"": ""Advantages of the drug "", ""type"": ""string""}, ""disadvantages"": {""title"": ""Disadvantages"", ""description"": ""Disadvantages of the drug"", ""type"": ""string""}}, ""required"": [""drug_name"", ""advantages"", ""disadvantages""]}
```

Question: question
Answer:
","""I don't know""",,,,,,,"title:

filename: otad009.pdf

page: 14

text: moderately to severely active UC.
Supplementary Data
Supplementary data is available at Crohn’s and Colitis 360
online.
Funding
This work was supported by AbbVie Inc., who funded this
study and participated in the study design, research, analy-
sis, data collection, interpretation of data, reviewing, and ap-
proval of the publication. All authors had access to relevant
data and participated in the drafting, review, and approval of
this publication. No honoraria or payments were made for
authorship. Medicus Economics LLC has received funding
from AbbVie Inc. for technical writing assistance.
Authors’ Contributions
Remo Panaccione: Writing—review and editing (equal), Eric
B. Collins: Methodology (supporting), formal analysis (e-","title: Approach to the Management of Recently Diagnosed Inflammatory Bowel Disease Patients: A User's Guide for Adult and Pediatric Gastroenterologists

filename: agrawal.pdf

page: 2

text: with an increased risk (odds ratio [OR], 2.1; 95% CI, 1.3–
3.6) of disabling disease 5 years after diagnosis, including
higher rates of surgery, hospitalization, steroid dependence,
and disease recurrence.42,43 In UC, younger age at diagnosis
is linked to more frequent relapses, colectomy, and colo-
rectal cancer.44,45 There are conﬂicting data on the disease
course in the very-early-onset IBD population of patients
diagnosed before age 6 years, with studies reporting both
similar
and
worse
outcomes
in
very-early-onset
IBD
compared to the general pediatric population.46 Similar to
the youngest patients with IBD, elderly-onset IBD (diag-
nosed at 60–65 years of age) has conﬂicting evidence on","title: First- and Second-Line Pharmacotherapies for Patients With Moderate to Severely Active Ulcerative Colitis: An Updated Network Meta-Analysis

filename: PIIS1542356520300446.pdf

page: 6

text: clinical
remission
and
endoscopic
improvement
in biologic-naïve patients
with moderate to severely
active ulcerative colitis. (B)
Relative
efﬁcacy
of
different interventions for
induction of clinical remis-
sion
and
endoscopic
improvement
in
patients
with moderate to severely
active
ulcerative
colitis
with prior exposure to tu-
mor necrosis factor (TNF)⍺
antagonists. SUCRA, sur-
face under the cumulative
ranking.
September 2020
Management of Moderate–Severe UC 2185","title:

filename: otad009.pdf

page: 0

text: Introduction
Ulcerative colitis (UC) is a chronic inflammatory bowel dis-
ease that affects the colorectum and is clinically characterized
by bloody diarrhea, urgency, tenesmus, abdominal pain, ma-
laise, weight loss, and fever. Disease onset commonly occurs
between the ages of 15 and 30 years and the annual global
© The Author(s) 2023. Published by Oxford University Press on behalf of Crohn's & Colitis Foundation.
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/),
which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.",,
4,"38 year old female with newly diagnosed moderate UC and psoriasis
",Ustekinumab,,,,Test treatment of specific EIM and IBD,"Make reference to the context given to assess the scenario. If you do not know the answer. just say that ""I don't know"", don't try to make up an answer.
You are a physician assistant giving advice on treatment for moderate to severe ulcerative colitis (UC). Perform the following step

ANALYSE the given patient profile based on given query based on the following criteria:
- Freshly treated patient or patient under maintenance
- Prior response to Infliximab
- Prior failure to Anti-TNF agents
- Prior failure to Vedolizumab
- Age
- Pregnancy
- Extraintestinale manifestations
- Pouchitis

FINALLY RETURN up to 2 TOP choices of biological drugs given patient profile. Explain the PROS and CONS of the 2 choices.

summaries

The output should be formatted as a JSON instance that conforms to the JSON schema below.

As an example, for the schema {""properties"": {""foo"": {""title"": ""Foo"", ""description"": ""a list of strings"", ""type"": ""array"", ""items"": {""type"": ""string""}}}, ""required"": [""foo""]}}
the object {""foo"": [""bar"", ""baz""]} is a well-formatted instance of the schema. The object {""properties"": {""foo"": [""bar"", ""baz""]}} is not well-formatted.

Here is the output schema:
```
{""properties"": {""drug_name"": {""title"": ""Drug Name"", ""description"": ""Name of the drug"", ""type"": ""string""}, ""advantages"": {""title"": ""Advantages"", ""description"": ""Advantages of the drug "", ""type"": ""string""}, ""disadvantages"": {""title"": ""Disadvantages"", ""description"": ""Disadvantages of the drug"", ""type"": ""string""}}, ""required"": [""drug_name"", ""advantages"", ""disadvantages""]}
```

Question: question
Answer:
",I don't know.,,,,,,,"title:

filename: otad009.pdf

page: 1

text: development for moderately to severely active UC. Most
recently, Lasa et al11 and Burr et al12 each conducted and
published a systematic literature review (SLR) and frequentist
network meta-analysis (NMA) on the efficacy and safety of
biologics and SMDs for patients with moderately to severely
UC. Both studies assessed all outcomes after induction (6–14
weeks); Lasa et al11 additionally assessed efficacy after main-
tenance (26–66 weeks) separately for treat-through (TT) and
re-randomized responders (RR) randomized clinical trials
(RCTs). Both studies also assessed all outcomes in overall
populations, as well as induction efficacy outcomes by prior
biologic exposure, though UPA was excluded from subgroup","title:

filename: otad009.pdf

page: 14

text: moderately to severely active UC.
Supplementary Data
Supplementary data is available at Crohn’s and Colitis 360
online.
Funding
This work was supported by AbbVie Inc., who funded this
study and participated in the study design, research, analy-
sis, data collection, interpretation of data, reviewing, and ap-
proval of the publication. All authors had access to relevant
data and participated in the drafting, review, and approval of
this publication. No honoraria or payments were made for
authorship. Medicus Economics LLC has received funding
from AbbVie Inc. for technical writing assistance.
Authors’ Contributions
Remo Panaccione: Writing—review and editing (equal), Eric
B. Collins: Methodology (supporting), formal analysis (e-","title: First- and Second-Line Pharmacotherapies for Patients With Moderate to Severely Active Ulcerative Colitis: An Updated Network Meta-Analysis

filename: PIIS1542356520300446.pdf

page: 5

text: Table 1. Overall, the median average age of patients was
41 years (interquartile range, 40–42 y), and 60%
(interquartile range, 56%–63%) were men. The median
disease duration was 6.7 years (interquartile range,
6.0–7.8 y), and 49% (interquartile range, 46%–55%) of
patients had extensive colitis. A median of 40% (inter-
quartile range, 30%–50%) of patients were treated with
concomitant immunomodulators, and 51% (interquartile
range, 45%–57%) were on corticosteroids at baseline.
Patients across all trials and treatment arms were com-
parable in terms of baseline prognostic variables, inclu-
sion/exclusion
criteria,
and
co-interventions.
All
outcomes were assessed uniformly based on the stan-","title:

filename: otad009.pdf

page: 1

text: 2
Efficacy and Safety of Advanced Therapies
incidence ranges from 9 to 20 cases per 100 000 per year with
higher incidence in North America and Northern Europe.1
The advanced therapeutic armamentarium for adults
with moderately to severely active UC is rapidly evolving.
For over 20 years, biologics targeting specific inflamma-
tory pathways have been the mainstay, beginning with those
targeting tumor necrosis alpha (TNFi; eg, infliximab [INF],
adalimumab [ADA], and golimumab [GOL]) followed by
biologics with other modes of action (eg, vedolizumab [VED]
and ustekinumab [UST]). However, treatment limitations for
moderately to severely active UC remain, including primary
nonresponse, secondary loss of response, immunogenicity, and",,
5,"25 year old pregnant woman with severe distal ulcerative colitis
",Infliximab,Vedolizumab,Ustekinumab,,Infliximab has best safety data in pregnancy (due to experience),"Make reference to the context given to assess the scenario. If you do not know the answer. just say that ""I don't know"", don't try to make up an answer.
You are a physician assistant giving advice on treatment for moderate to severe ulcerative colitis (UC). Perform the following step

ANALYSE the given patient profile based on given query based on the following criteria:
- Freshly treated patient or patient under maintenance
- Prior response to Infliximab
- Prior failure to Anti-TNF agents
- Prior failure to Vedolizumab
- Age
- Pregnancy
- Extraintestinale manifestations
- Pouchitis

FINALLY RETURN up to 2 TOP choices of biological drugs given patient profile. Explain the PROS and CONS of the 2 choices.

summaries

The output should be formatted as a JSON instance that conforms to the JSON schema below.

As an example, for the schema {""properties"": {""foo"": {""title"": ""Foo"", ""description"": ""a list of strings"", ""type"": ""array"", ""items"": {""type"": ""string""}}}, ""required"": [""foo""]}}
the object {""foo"": [""bar"", ""baz""]} is a well-formatted instance of the schema. The object {""properties"": {""foo"": [""bar"", ""baz""]}} is not well-formatted.

Here is the output schema:
```
{""properties"": {""drug_name"": {""title"": ""Drug Name"", ""description"": ""Name of the drug"", ""type"": ""string""}, ""advantages"": {""title"": ""Advantages"", ""description"": ""Advantages of the drug "", ""type"": ""string""}, ""disadvantages"": {""title"": ""Disadvantages"", ""description"": ""Disadvantages of the drug"", ""type"": ""string""}}, ""required"": [""drug_name"", ""advantages"", ""disadvantages""]}
```

Question: question
Answer:
",I don't know,,,,,,,"title:

filename: otad009.pdf

page: 0

text: Introduction
Ulcerative colitis (UC) is a chronic inflammatory bowel dis-
ease that affects the colorectum and is clinically characterized
by bloody diarrhea, urgency, tenesmus, abdominal pain, ma-
laise, weight loss, and fever. Disease onset commonly occurs
between the ages of 15 and 30 years and the annual global
© The Author(s) 2023. Published by Oxford University Press on behalf of Crohn's & Colitis Foundation.
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/),
which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.","title: Approach to the Management of Recently Diagnosed Inflammatory Bowel Disease Patients: A User's Guide for Adult and Pediatric Gastroenterologists

filename: agrawal.pdf

page: 2

text: with an increased risk (odds ratio [OR], 2.1; 95% CI, 1.3–
3.6) of disabling disease 5 years after diagnosis, including
higher rates of surgery, hospitalization, steroid dependence,
and disease recurrence.42,43 In UC, younger age at diagnosis
is linked to more frequent relapses, colectomy, and colo-
rectal cancer.44,45 There are conﬂicting data on the disease
course in the very-early-onset IBD population of patients
diagnosed before age 6 years, with studies reporting both
similar
and
worse
outcomes
in
very-early-onset
IBD
compared to the general pediatric population.46 Similar to
the youngest patients with IBD, elderly-onset IBD (diag-
nosed at 60–65 years of age) has conﬂicting evidence on","title:

filename: otad009.pdf

page: 11

text: Downloaded from https://academic.oup.com/crohnscolitis360/article/5/2/otad009/7066911 by National University of Singapore user on 23 May 2023","title: Approach to the Management of Recently Diagnosed Inflammatory Bowel Disease Patients: A Users Guide for Adult and Pediatric Gastroenterologists

filename: agrawal.pdf

page: 7

text: Therapeutic strategies for the management of recentlydiagnosedulcerative colitis. IMMs include thiopurines and methotrexate. 5-ASA, 5-amino salicylic acid; ASUC, acute severe ulcerative colitis; IPAA, ileal pouch anal anastomosis.

Risk stratification: Mild
Clinical features: NA
Treatment options: 5-ASA (oral and/or topical)

Risk stratification: Moderate
Clinical features: NA
Treatment options: Can consider 5-ASA (with rapid step-up if inadequate response)

Risk stratification: Moderate
Clinical features: NA
Treatment options: VDZ or UST

Risk stratification: Moderate
Clinical features: NA
Treatment options: Thiopurine

Risk stratification: Moderate
Clinical features: NA
Treatment options: TNFi +/- IMM

Risk stratification: Severe
Clinical features: NA
Treatment options: TNFi +/- IMM

Risk stratification: Severe
Clinical features: NA
Treatment options: Subtotal colectomy + IPAA or cyclosporine (for ASUC)

Risk stratification: Additional consideration: EIM present
Clinical features: Psoriasis or psoriatic arthritis
Treatment options: UST

Risk stratification: Additional consideration: EIM present
Clinical features: Other arthritis
Treatment options: TNFi

",,
6,"56 year old man with moderate to severe ulcerative colitis and ankylosing spondylitis
",Infliximab,Adalimumab,,,Dual indications,"Make reference to the context given to assess the scenario. If you do not know the answer. just say that ""I don't know"", don't try to make up an answer.
You are a physician assistant giving advice on treatment for moderate to severe ulcerative colitis (UC). Perform the following step

ANALYSE the given patient profile based on given query based on the following criteria:
- Freshly treated patient or patient under maintenance
- Prior response to Infliximab
- Prior failure to Anti-TNF agents
- Prior failure to Vedolizumab
- Age
- Pregnancy
- Extraintestinale manifestations
- Pouchitis

FINALLY RETURN up to 2 TOP choices of biological drugs given patient profile. Explain the PROS and CONS of the 2 choices.

summaries

The output should be formatted as a JSON instance that conforms to the JSON schema below.

As an example, for the schema {""properties"": {""foo"": {""title"": ""Foo"", ""description"": ""a list of strings"", ""type"": ""array"", ""items"": {""type"": ""string""}}}, ""required"": [""foo""]}}
the object {""foo"": [""bar"", ""baz""]} is a well-formatted instance of the schema. The object {""properties"": {""foo"": [""bar"", ""baz""]}} is not well-formatted.

Here is the output schema:
```
{""properties"": {""drug_name"": {""title"": ""Drug Name"", ""description"": ""Name of the drug"", ""type"": ""string""}, ""advantages"": {""title"": ""Advantages"", ""description"": ""Advantages of the drug "", ""type"": ""string""}, ""disadvantages"": {""title"": ""Disadvantages"", ""description"": ""Disadvantages of the drug"", ""type"": ""string""}}, ""required"": [""drug_name"", ""advantages"", ""disadvantages""]}
```

Question: question
Answer:
",I don't know.,,,,,,,"title:

filename: otad009.pdf

page: 0

text: Introduction
Ulcerative colitis (UC) is a chronic inflammatory bowel dis-
ease that affects the colorectum and is clinically characterized
by bloody diarrhea, urgency, tenesmus, abdominal pain, ma-
laise, weight loss, and fever. Disease onset commonly occurs
between the ages of 15 and 30 years and the annual global
© The Author(s) 2023. Published by Oxford University Press on behalf of Crohn's & Colitis Foundation.
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/),
which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.","title: First- and Second-Line Pharmacotherapies for Patients With Moderate to Severely Active Ulcerative Colitis: An Updated Network Meta-Analysis

filename: PIIS1542356520300446.pdf

page: 6

text: clinical
remission
and
endoscopic
improvement
in biologic-naïve patients
with moderate to severely
active ulcerative colitis. (B)
Relative
efﬁcacy
of
different interventions for
induction of clinical remis-
sion
and
endoscopic
improvement
in
patients
with moderate to severely
active
ulcerative
colitis
with prior exposure to tu-
mor necrosis factor (TNF)⍺
antagonists. SUCRA, sur-
face under the cumulative
ranking.
September 2020
Management of Moderate–Severe UC 2185","title: First- and Second-Line Pharmacotherapies for Patients With Moderate to Severely Active Ulcerative Colitis: An Updated Network Meta-Analysis

filename: PIIS1542356520300446.pdf

page: 5

text: Table 1. Overall, the median average age of patients was
41 years (interquartile range, 40–42 y), and 60%
(interquartile range, 56%–63%) were men. The median
disease duration was 6.7 years (interquartile range,
6.0–7.8 y), and 49% (interquartile range, 46%–55%) of
patients had extensive colitis. A median of 40% (inter-
quartile range, 30%–50%) of patients were treated with
concomitant immunomodulators, and 51% (interquartile
range, 45%–57%) were on corticosteroids at baseline.
Patients across all trials and treatment arms were com-
parable in terms of baseline prognostic variables, inclu-
sion/exclusion
criteria,
and
co-interventions.
All
outcomes were assessed uniformly based on the stan-","title: First- and Second-Line Pharmacotherapies for Patients With Moderate to Severely Active Ulcerative Colitis: An Updated Network Meta-Analysis

filename: PIIS1542356520300446.pdf

page: 0

text: patients have a mild–moderate course, approximately
10% to 15% of patients experience a severe disease
course with signiﬁcant morbidity, with frequent ﬂares
and
hospitalizations
requiring
immunosuppressive
therapies and corticosteroids, and impose a signiﬁcant
direct and indirect economic burden in population-
based cohorts.2,3 Several treatment options now are
available
for
the
management
of
moderate–severe
ulcerative colitis, with variable efﬁcacy and safety pro-
ﬁles, and positioning different agents in the treatment
course as ﬁrst-line (in biologic-naïve patients) and
Abbreviations used in this paper: GRADE, Grading of Recommendations
Assessment, Development and Evaluation; OCTAVE, Oral Clinical Trials",,
7,"38 year old man with severe ulcerative colitis and has lost response to vedolizumab
",Tofacitinib or ,Ustekinumab,,,Biologic failure,"Make reference to the context given to assess the scenario. If you do not know the answer. just say that ""I don't know"", don't try to make up an answer.
You are a physician assistant giving advice on treatment for moderate to severe ulcerative colitis (UC). Perform the following step

ANALYSE the given patient profile based on given query based on the following criteria:
- Freshly treated patient or patient under maintenance
- Prior response to Infliximab
- Prior failure to Anti-TNF agents
- Prior failure to Vedolizumab
- Age
- Pregnancy
- Extraintestinale manifestations
- Pouchitis

FINALLY RETURN up to 2 TOP choices of biological drugs given patient profile. Explain the PROS and CONS of the 2 choices.

summaries

The output should be formatted as a JSON instance that conforms to the JSON schema below.

As an example, for the schema {""properties"": {""foo"": {""title"": ""Foo"", ""description"": ""a list of strings"", ""type"": ""array"", ""items"": {""type"": ""string""}}}, ""required"": [""foo""]}}
the object {""foo"": [""bar"", ""baz""]} is a well-formatted instance of the schema. The object {""properties"": {""foo"": [""bar"", ""baz""]}} is not well-formatted.

Here is the output schema:
```
{""properties"": {""drug_name"": {""title"": ""Drug Name"", ""description"": ""Name of the drug"", ""type"": ""string""}, ""advantages"": {""title"": ""Advantages"", ""description"": ""Advantages of the drug "", ""type"": ""string""}, ""disadvantages"": {""title"": ""Disadvantages"", ""description"": ""Disadvantages of the drug"", ""type"": ""string""}}, ""required"": [""drug_name"", ""advantages"", ""disadvantages""]}
```

Question: question
Answer:
","[
  {
    ""drug_name"": ""Infliximab"",
    ""advantages"": ""Infliximab is recommended as first-line therapy for moderate to severe ulcerative colitis. It has been proven effective in clinical trials and is widely used in practice."",
    ""disadvantages"": ""Infliximab is an immunosuppressive drug, which means it can increase the risk of infections. It can also cause allergic reactions in some patients.""
  },
  {
    ""drug_name"": ""Tofacitinib"",
    ""advantages"": ""Tofacitinib is recommended for patients who have had prior exposure to TNF antagonists. It is a small molecule drug that can be taken orally, which may be more convenient for some patients."",
    ""disadvantages"": ""Tofacitinib can increase the risk of serious infections, malignancies, and thrombosis. It may also cause elevated cholesterol levels and liver enzyme elevations.""
  }
]",Infliximab,Infliximab is recommended as first-line therapy for moderate to severe ulcerative colitis. It has been proven effective in clinical trials and is widely used in practice.,"Infliximab is an immunosuppressive drug, which means it can increase the risk of infections. It can also cause allergic reactions in some patients.",Tofacitinib,"Tofacitinib is recommended for patients who have had prior exposure to TNF antagonists. It is a small molecule drug that can be taken orally, which may be more convenient for some patients.","Tofacitinib can increase the risk of serious infections, malignancies, and thrombosis. It may also cause elevated cholesterol levels and liver enzyme elevations.","title: First- and Second-Line Pharmacotherapies for Patients With Moderate to Severely Active Ulcerative Colitis: An Updated Network Meta-Analysis

filename: PIIS1542356520300446.pdf

page: 1

text: needed to inform clinical decision-making with
greater conﬁdence.
Implications for patient care
Patients with moderate to severely active ulcerative
colitis should receive inﬂiximab or vedolizumab as
ﬁrst-line therapy, or ustekinumab or tofacitinib if
they have prior exposure to TNF antagonists.
2180 Singh et al
Clinical Gastroenterology and Hepatology Vol. 18, No. 10","title: Efficacy and safety of biologics and small molecule drugs for patients with moderate-to-severe ulcerative colitis: a systematic review and network meta-analysis

filename: 1-s2.0-S2468125321003770-main.pdf

page: 0

text: colitis. Vedolizumab was the best performing agent for safety outcomes. With the paucity of direct comparisons in the
published literature, our results might help clinicians to position drugs in treatment algorithms.
Funding None.
Copyright © 2021 Elsevier Ltd. All rights reserved.
Introduction
Ulcerative colitis is a chronic, idiopathic, potentially
disabling condition that is clinically characterised
by bloody diarrhoea, abdominal pain, and tenesmus.1
Ulcerative colitis most commonly presents during the
third and fifth decades of life, and is associated with an
impaired health-related quality of life and considerable
economic burden.2,3
Nearly 20 years ago, the advent of anti-tumour necrosis","title: First- and Second-Line Pharmacotherapies for Patients With Moderate to Severely Active Ulcerative Colitis: An Updated Network Meta-Analysis

filename: PIIS1542356520300446.pdf

page: 11

text: 3.
Vester-Andersen MK, Prosberg MV, Jess T, et al. Disease
course and surgery rates in inﬂammatory bowel disease: a
population-based, 7-year follow-up study in the era of immu-
nomodulating therapy. Am J Gastroenterol 2014;109:705–714.
4.
Bonovas S, Lytras T, Nikolopoulos G, et al. Systematic review
with network meta-analysis: comparative assessment of tofa-
citinib and biological therapies for moderate-to-severe ulcera-
tive colitis. Aliment Pharmacol Ther 2018;47:454–465.
5.
Singh S, Fumery M, Sandborn WJ, et al. Systematic review with
network meta-analysis: ﬁrst- and second-line pharmacotherapy
for moderate-severe ulcerative colitis. Aliment Pharmacol Ther
2018;47:162–175.
6.
Sands BE, Peyrin-Biroulet L, Loftus EV Jr, et al. Vedolizumab","title: Positioning biologics in the treatment of IBD: A practical guide - Which mechanism of action for whom?

filename: juillerat 2022.pdf

page: 5

text: Cheng, D., Cushing, K.C., Cai, T., Ananthakrishnan, A.N., 2021. Safety and efﬁcacy of
tumor necrosis factor antagonists in older patients with ulcerative colitis: patient-
level pooled analysis of data from randomized trials. Clin. Gastroenterol. Hepatol. 19
(5), 939–946.
Christensen, B., Micic, D., Gibson, P.R., Yarur, A., Bellaguarda, E., Corsello, P.,
Gaetano, J.N., Kinnucan, J., Rao, V.L., Reddy, S., Singh, S., Pekow, J., Rubin, D.T.,
2018. Vedolizumab in patients with concurrent primary sclerosing cholangitis and
inﬂammatory bowel disease does not improve liver biochemistry but is safe and
effective for the bowel disease. Aliment. Pharmacol. Ther. 47 (6), 753–762.",,
8,"28 year old woman who has severe extensive ulcerative colitis and has a history of lymphoma which was treated 4 years ago
",Vedolizumab,Ustekinumab,,,Anti-TNFs and JAK inhs have associations/concerns with malignancies,"Make reference to the context given to assess the scenario. If you do not know the answer. just say that ""I don't know"", don't try to make up an answer.
You are a physician assistant giving advice on treatment for moderate to severe ulcerative colitis (UC). Perform the following step

ANALYSE the given patient profile based on given query based on the following criteria:
- Freshly treated patient or patient under maintenance
- Prior response to Infliximab
- Prior failure to Anti-TNF agents
- Prior failure to Vedolizumab
- Age
- Pregnancy
- Extraintestinale manifestations
- Pouchitis

FINALLY RETURN up to 2 TOP choices of biological drugs given patient profile. Explain the PROS and CONS of the 2 choices.

summaries

The output should be formatted as a JSON instance that conforms to the JSON schema below.

As an example, for the schema {""properties"": {""foo"": {""title"": ""Foo"", ""description"": ""a list of strings"", ""type"": ""array"", ""items"": {""type"": ""string""}}}, ""required"": [""foo""]}}
the object {""foo"": [""bar"", ""baz""]} is a well-formatted instance of the schema. The object {""properties"": {""foo"": [""bar"", ""baz""]}} is not well-formatted.

Here is the output schema:
```
{""properties"": {""drug_name"": {""title"": ""Drug Name"", ""description"": ""Name of the drug"", ""type"": ""string""}, ""advantages"": {""title"": ""Advantages"", ""description"": ""Advantages of the drug "", ""type"": ""string""}, ""disadvantages"": {""title"": ""Disadvantages"", ""description"": ""Disadvantages of the drug"", ""type"": ""string""}}, ""required"": [""drug_name"", ""advantages"", ""disadvantages""]}
```

Question: question
Answer:
","{""drug_name"": ""Vedolizumab"", ""advantages"": ""Vedolizumab is a first-line therapy for moderate to severely active ulcerative colitis. It is especially beneficial for patients who have had prior exposure to TNF antagonists. It is also a good choice for this patient due to her history of lymphoma, as Vedolizumab has a lower risk of reactivating latent infections or causing malignancies compared to other biologics."", ""disadvantages"": ""The main disadvantage of Vedolizumab is that it may take longer to work compared to other biologics. It also requires intravenous administration, which can be inconvenient for some patients.""},

{""drug_name"": ""Ustekinumab"", ""advantages"": ""Ustekinumab can be used if the patient has prior exposure to TNF antagonists. It is also a good choice for this patient due to her history of lymphoma, as Ustekinumab has a lower risk of reactivating latent infections or causing malignancies compared to other biologics."", ""disadvantages"": ""The main disadvantage of Ustekinumab is that it may not be as effective as other biologics in inducing remission in ulcerative colitis. It also requires subcutaneous administration, which can be inconvenient for some patients.""}",Vedolizumab,"Vedolizumab is a first-line therapy for moderate to severely active ulcerative colitis. It is especially beneficial for patients who have had prior exposure to TNF antagonists. It is also a good choice for this patient due to her history of lymphoma, as Vedolizumab has a lower risk of reactivating latent infections or causing malignancies compared to other biologics.","The main disadvantage of Vedolizumab is that it may take longer to work compared to other biologics. It also requires intravenous administration, which can be inconvenient for some patients.",Ustekinumab,"Ustekinumab can be used if the patient has prior exposure to TNF antagonists. It is also a good choice for this patient due to her history of lymphoma, as Ustekinumab has a lower risk of reactivating latent infections or causing malignancies compared to other biologics.","The main disadvantage of Ustekinumab is that it may not be as effective as other biologics in inducing remission in ulcerative colitis. It also requires subcutaneous administration, which can be inconvenient for some patients.","title:

filename: otad009.pdf

page: 0

text: Introduction
Ulcerative colitis (UC) is a chronic inflammatory bowel dis-
ease that affects the colorectum and is clinically characterized
by bloody diarrhea, urgency, tenesmus, abdominal pain, ma-
laise, weight loss, and fever. Disease onset commonly occurs
between the ages of 15 and 30 years and the annual global
© The Author(s) 2023. Published by Oxford University Press on behalf of Crohn's & Colitis Foundation.
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/),
which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.","title: First- and Second-Line Pharmacotherapies for Patients With Moderate to Severely Active Ulcerative Colitis: An Updated Network Meta-Analysis

filename: PIIS1542356520300446.pdf

page: 1

text: needed to inform clinical decision-making with
greater conﬁdence.
Implications for patient care
Patients with moderate to severely active ulcerative
colitis should receive inﬂiximab or vedolizumab as
ﬁrst-line therapy, or ustekinumab or tofacitinib if
they have prior exposure to TNF antagonists.
2180 Singh et al
Clinical Gastroenterology and Hepatology Vol. 18, No. 10","title: First- and Second-Line Pharmacotherapies for Patients With Moderate to Severely Active Ulcerative Colitis: An Updated Network Meta-Analysis

filename: PIIS1542356520300446.pdf

page: 1

text: colitis.
Studies
included
in
these
meta-
analyses were phase II or III randomized controlled
trials (RCTs) that met the following inclusion criteria:
(1) patients: adults (age, >18 y) with moderate to
severe ulcerative colitis (Mayo Clinic score of 6–12,
with an endoscopic subscore of 2 or 3) who were
either
treatment-naïve
(ﬁrst-line)
or
previously
exposed to TNFa antagonists (second-line); (2) inter-
vention: biologic therapy with inﬂiximab, adalimumab,
golimumab, vedolizumab, tofacitinib, or ustekinumab,
with a minimum duration of therapy of 14 days; (3)
comparator: another active intervention or placebo;
and (4) outcome: induction of clinical remission (Mayo
Clinic score of �2 with no individual subscore of >1)","title: First- and Second-Line Pharmacotherapies for Patients With Moderate to Severely Active Ulcerative Colitis: An Updated Network Meta-Analysis

filename: PIIS1542356520300446.pdf

page: 6

text: clinical
remission
and
endoscopic
improvement
in biologic-naïve patients
with moderate to severely
active ulcerative colitis. (B)
Relative
efﬁcacy
of
different interventions for
induction of clinical remis-
sion
and
endoscopic
improvement
in
patients
with moderate to severely
active
ulcerative
colitis
with prior exposure to tu-
mor necrosis factor (TNF)⍺
antagonists. SUCRA, sur-
face under the cumulative
ranking.
September 2020
Management of Moderate–Severe UC 2185",,
9,36 year old woman with moderate ulcerative colitis and multiple sclerosis,Ozanimod,Etrasimod,,,Dual indications,"Make reference to the context given to assess the scenario. If you do not know the answer. just say that ""I don't know"", don't try to make up an answer.
You are a physician assistant giving advice on treatment for moderate to severe ulcerative colitis (UC). Perform the following step

ANALYSE the given patient profile based on given query based on the following criteria:
- Freshly treated patient or patient under maintenance
- Prior response to Infliximab
- Prior failure to Anti-TNF agents
- Prior failure to Vedolizumab
- Age
- Pregnancy
- Extraintestinale manifestations
- Pouchitis

FINALLY RETURN up to 2 TOP choices of biological drugs given patient profile. Explain the PROS and CONS of the 2 choices.

summaries

The output should be formatted as a JSON instance that conforms to the JSON schema below.

As an example, for the schema {""properties"": {""foo"": {""title"": ""Foo"", ""description"": ""a list of strings"", ""type"": ""array"", ""items"": {""type"": ""string""}}}, ""required"": [""foo""]}}
the object {""foo"": [""bar"", ""baz""]} is a well-formatted instance of the schema. The object {""properties"": {""foo"": [""bar"", ""baz""]}} is not well-formatted.

Here is the output schema:
```
{""properties"": {""drug_name"": {""title"": ""Drug Name"", ""description"": ""Name of the drug"", ""type"": ""string""}, ""advantages"": {""title"": ""Advantages"", ""description"": ""Advantages of the drug "", ""type"": ""string""}, ""disadvantages"": {""title"": ""Disadvantages"", ""description"": ""Disadvantages of the drug"", ""type"": ""string""}}, ""required"": [""drug_name"", ""advantages"", ""disadvantages""]}
```

Question: question
Answer:
",I don't know.,,,,,,,"title:

filename: otad009.pdf

page: 0

text: Introduction
Ulcerative colitis (UC) is a chronic inflammatory bowel dis-
ease that affects the colorectum and is clinically characterized
by bloody diarrhea, urgency, tenesmus, abdominal pain, ma-
laise, weight loss, and fever. Disease onset commonly occurs
between the ages of 15 and 30 years and the annual global
© The Author(s) 2023. Published by Oxford University Press on behalf of Crohn's & Colitis Foundation.
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/),
which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.","title: First- and Second-Line Pharmacotherapies for Patients With Moderate to Severely Active Ulcerative Colitis: An Updated Network Meta-Analysis

filename: PIIS1542356520300446.pdf

page: 5

text: Table 1. Overall, the median average age of patients was
41 years (interquartile range, 40–42 y), and 60%
(interquartile range, 56%–63%) were men. The median
disease duration was 6.7 years (interquartile range,
6.0–7.8 y), and 49% (interquartile range, 46%–55%) of
patients had extensive colitis. A median of 40% (inter-
quartile range, 30%–50%) of patients were treated with
concomitant immunomodulators, and 51% (interquartile
range, 45%–57%) were on corticosteroids at baseline.
Patients across all trials and treatment arms were com-
parable in terms of baseline prognostic variables, inclu-
sion/exclusion
criteria,
and
co-interventions.
All
outcomes were assessed uniformly based on the stan-","title: First- and Second-Line Pharmacotherapies for Patients With Moderate to Severely Active Ulcerative Colitis: An Updated Network Meta-Analysis

filename: PIIS1542356520300446.pdf

page: 6

text: clinical
remission
and
endoscopic
improvement
in biologic-naïve patients
with moderate to severely
active ulcerative colitis. (B)
Relative
efﬁcacy
of
different interventions for
induction of clinical remis-
sion
and
endoscopic
improvement
in
patients
with moderate to severely
active
ulcerative
colitis
with prior exposure to tu-
mor necrosis factor (TNF)⍺
antagonists. SUCRA, sur-
face under the cumulative
ranking.
September 2020
Management of Moderate–Severe UC 2185","title: First- and Second-Line Pharmacotherapies for Patients With Moderate to Severely Active Ulcerative Colitis: An Updated Network Meta-Analysis

filename: PIIS1542356520300446.pdf

page: 0

text: patients have a mild–moderate course, approximately
10% to 15% of patients experience a severe disease
course with signiﬁcant morbidity, with frequent ﬂares
and
hospitalizations
requiring
immunosuppressive
therapies and corticosteroids, and impose a signiﬁcant
direct and indirect economic burden in population-
based cohorts.2,3 Several treatment options now are
available
for
the
management
of
moderate–severe
ulcerative colitis, with variable efﬁcacy and safety pro-
ﬁles, and positioning different agents in the treatment
course as ﬁrst-line (in biologic-naïve patients) and
Abbreviations used in this paper: GRADE, Grading of Recommendations
Assessment, Development and Evaluation; OCTAVE, Oral Clinical Trials",,
